Core Insights - OpenEvidence is emerging as a transformative product in the U.S. healthcare system, being referred to as the "Google of medicine" and "doctor's ChatGPT," with a valuation of $6 billion and usage by 40% of U.S. doctors [1][6] - The company recently completed a $200 million funding round led by Google Ventures, raising its valuation from $3.5 billion in July [1][6] - The founder, Daniel Nadler, identified that modern doctors are overwhelmed by the vast amount of medical literature, with knowledge becoming outdated quickly [2][3] Group 1: Company Overview - OpenEvidence was founded in 2021 by Daniel Nadler and Zachary Ziegler, who invested $10 million of their own funds [3] - The company focuses on providing evidence-based medical information, addressing the challenge of extracting useful insights from millions of research papers [2][6] - The platform has evolved from a "verifiable medical search engine" to a clinical decision assistant, acting as a "second brain" for doctors [6][7] Group 2: Technology and Model - OpenEvidence utilizes a specialized model trained on high-quality public data from sources like FDA and CDC, ensuring authoritative content without hallucinations [6] - The platform's unique "no hallucination" mechanism has gained the trust of doctors, differentiating it from traditional search engines [6] - The company has adopted a direct-to-clinician model, allowing doctors to access the platform for free after identity verification, leading to explosive growth in usage [6][7] Group 3: User Engagement and Growth - Monthly clinical consultations surged from 358,000 in 2024 to 16.5 million in 2025, with over 430,000 registered doctors [6][7] - OpenEvidence's DeepConsult feature analyzes multiple studies to provide comprehensive recommendations for complex cases [7] - The platform has become the first AI system to achieve a 100% score on the U.S. medical licensing exam, attracting partnerships with prestigious medical journals [7] Group 4: Business Model and Revenue - OpenEvidence's business model is similar to Google's, offering free access to doctors while generating revenue from pharmaceutical advertising [7] - The company is projected to reach an annual recurring revenue (ARR) of $50 million by July and expects to exceed $100 million by 2026 [7] - The cost per thousand impressions (CPM) for its ads ranges from $70 to $150, significantly higher than social media platforms [7]